Cellect Biotechnology: Rises after co receives approval for U.S. clinical trial

Quoin Pharmaceuticals

23/12/2019 13:37

** U.S.-listed shares of Israel-based stem cell therapy
developer  APOP.O  up 6.8% at $2.35 premarket
    ** Co receives approval for U.S. clinical trial to assess
technology for bone marrow transplant  urn:newsml:reuters.com:*:nPn6xW08la
    ** Says 18 patients planned for initial phase, with
enrollment expected to begin in first half of 2020
    ** Up to Friday's close, stock had fallen ~79% YTD

 (Reporting by Arunima Kumar in Bengaluru)
 ((Arunima.Kumar@thomsonreuters.com))